A Phase 1 Relative Bioavailability Study in Healthy CYP2D6 Intermediate (IM) and Extensive Metaboliser (EM) Subjects, Designed to Evaluate the Pharmacokinetic (PK) Profile of HTL0009936 Following Single Dose Administration of Modified Release (MR) Prototype Formulations
Latest Information Update: 17 Sep 2021
At a glance
- Drugs HTL 9936 (Primary) ; HTL 9936
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Heptares Therapeutics
- 17 Oct 2016 Status changed from recruiting to completed.
- 18 Mar 2016 New trial record